| Over a month ago | ||||
New option listings for… New option listings for December 21st include CLSA ETF (CLSA), Cobalis Corporation (CLSC), CLVSQ Stock (CLVSQ), DFIC ETF (DFIC), GSUS ETF (GSUS), JIRE ETF (JIRE), Metrocity Bankshares Inc (MCBS), OmniAb (OABI), Orrstown Financial (ORRF), PFIX ETF (PFIX), Parke Bancorp (PKBK), POINT Biopharma Global Inc (PNT), RBB Bancorp (RBB), RMR Group (RMR), and UHALB Stock (UHALB). | ||||
Truist analyst Robyn… Truist analyst Robyn Karnauskas initiated coverage of OmniAb with a Buy rating and $10 price target. Unlike many SMID names, Karnauskas sees less binary risk and instead see steady progression to the firm's price target as OmniAb secures additional partners with improving economics as well as increased clarity on revenue streams from royalties and development milestones, the analyst tells investors in a research note. | ||||
Credit Suisse analyst… Credit Suisse analyst Tiago Fauth initiated coverage of OmniAb with an Outperform rating and $13 price target. The analyst expects the company's "flexibility and diversity of the multispecies platform" to drive growth. At the current valuation, the market is assigning value to some of the 25 clinical/approved programs but not to the company's remaining 257 preclinical programs, as there is no information on any of these programs, Fauth tells investors in a research note. | ||||
Healthcare Analyst… Healthcare Analyst Wasserman holds a conference call with CEO Foehr and CFO Gustafson on December 6 hosted by Benchmark. | ||||
Healthcare Analyst… Healthcare Analyst Wasserman holds a conference call with CEO Foehr and CFO Gustafson on December 6 hosted by Benchmark. | ||||
Hillstream BioPharma… Hillstream BioPharma (HILS) announced the development of proprietary targeted biologics, Knob Quatrabodies against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (OABI) and with Minotaur Therapeutics to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1. The technologies of Hillstream and Minotaur will be combined under a previously disclosed license from OmniAb to discover, develop and advance biotherapeutics against high-value validated targets. Picobodies are antibody "knob" domains comprised of cysteine-rich ultralong complementary determining region H3 sequences of 30-40 amino acids, which have the potential to access challenging epitopes better than full size antibodies can. By combining Quatramers with their long half-life coated with a PD-1 Picobody to create HSB-1940, Hillstream believes it could more efficiently target novel epitopes with greater binding affinity than approved biologics. Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology therapeutics market with additional IO targets after PD-L1. | ||||
SVB Securities analyst… SVB Securities analyst Puneet Souda initiated coverage of OmniAb with an Outperform rating and $6 price target. | ||||
Stifel analyst Stephen… Stifel analyst Stephen Willey initiated coverage of OmniAb with a Buy rating and $12 price target. OmniAb "represents the construction of a high-throughput antibody discovery platform" via over 10 years of focused investment and strategic acquisitions, Willey tells investors in a research note. The analyst believes the spin-off of OmniAb from Ligand "creates an opportunity to unlock additional value and better-position the company for future growth." | ||||
| Over a quarter ago | ||||
These names in the…
| ||||
